Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
MapLight’s ML-007C-MA Meets Primary Endpoint in Phase 2 Schizophrenia Trial
14+ hour, 6+ min ago (481+ words) The Clinical Trial Vanguard MapLight’s ML-007C-MA Meets Primary Endpoint in Phase 2 Schizophrenia Trial Cognitive improvement in schizophrenia trials rarely detaches from symptom scores, so the prespecified secondary endpoint in MapLight Therapeutics’ Phase 2 ZEPHYR trial deserves close attention: ML-007C-MA…...
LB Pharmaceuticals Accelerates NOVA-2 Schizophrenia Trial Readout
5+ day, 14+ hour ago (423+ words) The Clinical Trial Vanguard LB Pharmaceuticals Accelerates NOVA-2 Schizophrenia Trial Readout LB Pharmaceuticals is pulling forward the readout from its pivotal schizophrenia trial by a margin that, in a disease area where enrollment delays routinely stretch programs by a year…...
Tonix Launches Phase 2 HORIZON Trial of TNX-102 SL for Major Depressive Disorder
3+ week, 6+ day ago (466+ words) The Clinical Trial Vanguard Tonix Launches Phase 2 HORIZON Trial of TNX-102 SL for Major Depressive Disorder Antidepressants have historically targeted monoamine reuptake, yet roughly a third of patients with major depressive disorder fail to respond adequately to first-line treatment, and…...
What a 26-Trial Ketamine Meta-Analysis Gets Right, and What It Still Can’t Capture
1+ mon, 1+ day ago (740+ words) The Clinical Trial Vanguard What a 26-Trial Ketamine Meta-Analysis Gets Right, and What It Still Can’t Capture A patient I saw recently had failed four antidepressants over three years, including two augmentation strategies. She was functional, holding a job, maintaining…...
The Tobacco Exclusion That’s Distorting Every Psychosis-Prevention Trial You’re Running
1+ mon, 3+ week ago (1371+ words) The Clinical Trial Vanguard The Tobacco Exclusion That’s Distorting Every Psychosis-Prevention Trial You’re Running She was 21, Spanish-monolingual, referred from a community mental health clinic in Anaheim with a structured interview confirming attenuated psychotic symptoms and a SOPS score that put…...
Positive Phase 2B Results for Treatment-Resistant Depression
1+ year, 3+ week ago (92+ words) Atai Life Sciences and Beckley Psytech announced positive topline results from a Phase 2b trial of BPL-003 (intranasal mebufotenin) for treatment-resistant depression (TRD). Both 8mg and 12mg single doses showed statistically significant reductions in depressive symptoms compared to a low-dose control, with effects…...
The IT Neuron Finding That Should Reshape How We Design Rapid-Acting Depression Trials
2+ mon, 1+ week ago (741+ words) The Clinical Trial Vanguard The IT Neuron Finding That Should Reshape How We Design Rapid-Acting Depression Trials A patient I’ve been treating for three years — treatment-resistant MDD, two failed SSRIs, one failed SNRI, buprenorphine-maintained for co-occurring opioid use disorder — finally…...
First Patient Dosed in Tamarind Trial for MDD
1+ year, 5+ day ago (55+ words) HMNC Brain Health and Spruce Biosciences have dosed the first patient in the Phase 2 TAMARIND clinical trial. This trial is investigating tildacerfont, a CRF1 receptor antagonist, as a treatment for Major Depressive Disorder (MDD) in patients selected using HMNC's investigational patient selection…...
The GLP-1 Mood Signal Is Real — But So Is the Psychiatric Worsening Risk
3+ mon, 3+ week ago (1047+ words) The Clinical Trial Vanguard The GLP-1 Mood Signal Is Real — But So Is the Psychiatric Worsening Risk A pattern I’ve been tracking across my dual-diagnosis patient panel this year: the patients who come in asking about semaglutide are not the…...
Minerva Presents Safety Trial Data on Roluperidone, Olanzapine
4+ mon, 1+ day ago (556+ words) The Clinical Trial Vanguard Minerva Presents Safety Trial Data on Roluperidone, Olanzapine Minerva Neurosciences reported that an open-label safety study of roluperidone coadministered with olanzapine showed no clinically significant adverse effects and no meaningful PK or PD interactions. The company…...